Merck falls as investors weigh $6.7B Terns deal costs and Keytruda cliff risk
Merck shares are sliding as investors digest a cash outflow and near-term earnings charge tied to its $6.7 billion acquisition of Terns Pharmaceuticals. The decline also reflects renewed focus on the company’s post‑Keytruda growth path as its 2028 patent cliff approaches.
1. What’s driving MRK lower today
Merck (MRK) is down about 3% as traders refocus on the financial and strategic trade-offs of its recent oncology M&A. The company’s planned acquisition of Terns Pharmaceuticals, valued at roughly $6.7 billion, implies meaningful near-term cash usage and an expected acquisition-related charge that can pressure sentiment around earnings quality and near-term EPS optics.
2. The market’s core worry: replacing Keytruda growth
The selloff also reflects persistent investor sensitivity to Merck’s dependence on Keytruda ahead of expected loss of exclusivity in 2028. Even when a deal is strategically aligned—adding pipeline shots on goal—investors often demand clearer visibility into timing, probability of success, and how quickly new assets can translate into durable revenue that bridges the looming patent cliff.
3. What to watch next
Investors will be looking for (a) transaction progress and closing timeline for the Terns tender process, (b) any updates on Merck’s oncology lifecycle strategy for Keytruda, and (c) upcoming regulatory and pipeline milestones that can reshape 2026–2028 revenue expectations. The next few weeks of analyst note flow and estimate revisions can be as market-moving as the original deal headline.